Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Recruiting now · Phase 3

Conditions studied: T2DM, Diabete Type 2, DM

In brief

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

Key facts

Study ID

NCT07093476

Run by

Celltrion

People needed

171

Starts

2025-07-18

Expected to finish

2027-04-01

Last updated by the study team

2025-08-11

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults at the time of signing the Informed Consent Form (ICF)
• Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
• Diagnosed with T2DM

You may not qualify if…

• Diagnosed with other types of diabetes than T2DM
• History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy
• Uncontrolled severe complications of diabetes

Where it is running

• Celltrion — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.